Access to health in developing countries

Novo Nordisk is committed to help bring about a healthier global society.

It is clear to us that sustainable healthcare involves much more than simply producing healthcare products.

We believe it is part of our role as a responsible corporate citizen to engage as partners with a wide range of stakeholders in the developing countries to further the care and treatment of diabetes.

Novo Nordisk’s initiatives

The World Health Organisation (WHO) has identified four major focus areas for improving access to healthcare in developing countries:

  • Development of national disease strategies
  • Building of national healthcare capacity
  • Provision at best possible pricing
  • Additional funding

WHO's four priorities have been integrated into Novo Nordisk strategy for improving access to diabetes care in developing countries, and Novo Nordisk has identified activities to implement against each of them:

  • The National Diabetes Programmes (WHO's focus area 1 and 2)
  • The DAWN study (WHO's focus area 1 and 2)
  • A new pricing policy (WHO's focus area 3)
  • The World Diabetes Foundation (WHO's focus area 4).




Charlotte Ersbøll
Corporate Vice President,
Corporate Stakeholder Engagement
+45 3079 6511